SAREPTA THERAPEUTICS, INC. Amortization of Debt Discount (Premium)
SAREPTA THERAPEUTICS, INC. (SRPT) reported Amortization of Debt Discount (Premium) of $2.43 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2015-02-26
- SAREPTA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2014-12-31 was $615.00K.
- SAREPTA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2014-09-30 was $690.00K.
- SAREPTA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2014-06-30 was $608.00K.
- SAREPTA THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2014-03-31 was $519.00K.
- SAREPTA THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2014 was $2.43M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 404 month |
|---|---|---|---|---|---|
| 2014-12-31 | $615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $1.30M derived: sum of 2 quarters · filed 2015-02-26 | $1.91M derived: sum of 3 quarters · filed 2015-02-26 | $2.43M 10-K · filed 2015-02-26 | |
| 2014-09-30 | $690.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $1.30M derived: sum of 2 quarters · filed 2014-11-06 | $1.82M 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | $608.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.13M 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $519.00K 10-Q · filed 2014-05-08 | $519.00K 10-Q · filed 2014-05-08 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | |||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |